Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication
Brief Summary: This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of lebrikizumab in patients with asthma whose disease remains uncontrolled despite daily therapy with an inhaled corticosteroid and a second controller medication. Patients will be randomized in a 1:1:1:1 ratio to receive double-blind treatment with subcutaneous lebrikizumab ("highest", "middle", "lowest" dose) or placebo every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. The anticipated time on study treatment is up to 104 weeks. There will be a safety follow-up of 24 weeks after the last dose of study drug for all patients.


Options:
A: Arm Label: MEDI528 30 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 30 mg | Arm Label: MEDI528 100 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 100 mg | Arm Label: MEDI528 300 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 300 mg | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI528 30 mg; Assigned to Arm(s): MEDI528 30 mg | Intervention Type: BIOLOGICAL; Name: MEDI528 100 mg; Assigned to Arm(s): MEDI528 100 mg | Intervention Type: BIOLOGICAL; Name: MEDI528 300 mg; Assigned to Arm(s): MEDI528 300 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Mepolizumab; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab 300 mg, Drug: Active OCS capsules (5 mg prednisolone or prednisone), Drug: Placebo matching OCS capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matching mepolizumab, Drug: Active OCS capsules (5 mg prednisolone or prednisone), Drug: Placebo matching OCS capsules | Intervention Type: DRUG; Name: Mepolizumab 300 mg; Assigned to Arm(s): Mepolizumab | Intervention Type: DRUG; Name: Placebo matching mepolizumab; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Active OCS capsules (5 mg prednisolone or prednisone); Assigned to Arm(s): Mepolizumab, Placebo | Intervention Type: DRUG; Name: Placebo matching OCS capsules; Assigned to Arm(s): Mepolizumab, Placebo
C: Arm Label: lebrikizumab - highest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - lowest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - middle dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - highest dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - middle dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - lowest dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Benralizumab (Medi-563); Type: EXPERIMENTAL; Interventions: Drug: Benralizumab (Medi-563) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Benralizumab (Medi-563); Assigned to Arm(s): Benralizumab (Medi-563) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C